Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

bicalutamide

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Androgen receptor inhibitor

Related drugs:

‹

enzalutamide (78)

darolutamide (14)

SID 3712502 (1)

rezvilutamide (0)

enzalutamide tablet (0)

enzalutamide (78)

darolutamide (14)

SID 3712502 (1)

rezvilutamide (0)

enzalutamide tablet (0)

›

AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	bicalutamide + goserelin acetate Sensitive: A2 - Guideline bicalutamide + goserelin acetate Sensitive : A2	bicalutamide + goserelin acetate Sensitive: A2 - Guideline bicalutamide + goserelin acetate Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	bicalutamide + triptorelin Sensitive: A2 - Guideline bicalutamide + triptorelin Sensitive : A2	bicalutamide + triptorelin Sensitive: A2 - Guideline bicalutamide + triptorelin Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide acetate + bicalutamide Sensitive: A2 - Guideline leuprolide acetate + bicalutamide Sensitive : A2	leuprolide acetate + bicalutamide Sensitive: A2 - Guideline leuprolide acetate + bicalutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	bicalutamide + histrelin acetate Sensitive: A2 - Guideline bicalutamide + histrelin acetate Sensitive : A2	bicalutamide + histrelin acetate Sensitive: A2 - Guideline bicalutamide + histrelin acetate Sensitive : A2
PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	bicalutamide Sensitive: B - Late Trials bicalutamide Sensitive : B	bicalutamide Sensitive: B - Late Trials bicalutamide Sensitive : B
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
PLIN2 expression	Salivary Gland Cancer	PLIN2 expression	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
PTEN expression	Salivary Gland Cancer	PTEN expression	Salivary Gland Cancer	bicalutamide Sensitive: C3 – Early Trials bicalutamide Sensitive : C3	bicalutamide Sensitive: C3 – Early Trials bicalutamide Sensitive : C3
AR positive + HER-2 amplification	Salivary Gland Cancer	AR positive + HER-2 amplification	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C4 – Case Studies leuprolide acetate + bicalutamide Sensitive : C4	leuprolide acetate + bicalutamide Sensitive: C4 – Case Studies leuprolide acetate + bicalutamide Sensitive : C4
AR W741C	Prostate Cancer	AR W741C	Prostate Cancer	bicalutamide Resistant: D – Preclinical bicalutamide Resistant : D	bicalutamide Resistant: D – Preclinical bicalutamide Resistant : D
AR W741L	Prostate Cancer	AR W741L	Prostate Cancer	bicalutamide Resistant: D – Preclinical bicalutamide Resistant : D	bicalutamide Resistant: D – Preclinical bicalutamide Resistant : D
CFLAR expression	Prostate Cancer	CFLAR expression	Prostate Cancer	bicalutamide Resistant: D – Preclinical bicalutamide Resistant : D	bicalutamide Resistant: D – Preclinical bicalutamide Resistant : D